Sign In
Buy NNVC
$1.31
-0.0100 (-0.758%)
At Close: Jun 23, 2026
NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387
09:37am, Wednesday, 23'rd Jul 2025
NanoViricides (NYSE-A:NNVC) said on Wednesday that its broad-spectrum antiviral candidate NV-387 has shown strong preclinical efficacy against multiple viruses, positioning it as a potential tool in g
SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the developm
NanoViricides says lead antiviral boosted survival in measles-infected mice
08:36am, Monday, 21'st Jul 2025
NanoViricides (NYSE-A:NNVC) said on Monday that its broad-spectrum antiviral candidate, NV-387, showed strong effectiveness in preclinical studies using a humanized animal model. The Connecticut-based
Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides
06:30am, Monday, 21'st Jul 2025
SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of b
NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency
09:16am, Wednesday, 16'th Jul 2025
NanoViricides (NYSE-A:NNVC) is preparing for Phase II clinical testing in Africa, following the World Health Organization's recent extension of the Public Health Emergency of International Concern (PH
WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides
08:30am, Wednesday, 16'th Jul 2025
SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the develo
NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks
12:29pm, Tuesday, 15'th Jul 2025
NanoViricides (NYSE-A:NNVC) is preparing to launch a Phase 2 clinical trial of its lead antiviral candidate NV-387 for the treatment of Mpox Clade I in the Democratic Republic of Congo (DRC), followin
NanoViricides nears completion of clinical trial design for MPox treatment
08:52am, Monday, 14'th Jul 2025
NanoViricides (NYSE-A:NNVC) said on Monday it is close to finalizing the design of a Phase II adaptive clinical trial for its lead candidate NV-387 to treat MPox virus Clade 1a and 1b infections. The
NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox
08:36am, Wednesday, 02'nd Jul 2025
NanoViricides (NYSE-A:NNVC) announced it is moving forward with Phase 2 clinical development of its experimental antiviral therapy, NV-387, for the treatment of Mpox. The company has selected Mpox as
SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of bro
NanoViricides touts antiviral NV-387 as tool against new COVID variant
08:36am, Wednesday, 18'th Jun 2025
NanoViricides (NYSE-A:NNVC) said its experimental antiviral drug NV-387 could play a role in combating emerging threats from COVID-19 and bird flu, as new virus variants raise global health concerns.
SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the s
NanoViricides commissions animal study of broad-spectrum antiviral for measles
09:03am, Wednesday, 04'th Jun 2025
NanoViricides (NYSE-A:NNVC) said it is advancing its measles drug development program with a new animal trial to evaluate its antiviral candidate NV-387. The company has commissioned a study using spe
NanoViricides Measles Drug Development Animal Study is Imminent
06:55am, Wednesday, 04'th Jun 2025
SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broa
NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025
06:30am, Wednesday, 28'th May 2025
SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus
